Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Nexcella, Inc. California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) July 25, 2024 From Nexcella, Inc. Via GlobeNewswire Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States April 18, 2024 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board January 04, 2024 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board December 18, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 December 11, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing November 21, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients November 06, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients November 06, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board October 26, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site October 16, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting October 03, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma October 02, 2023 From Nexcella, Inc. Via GlobeNewswire U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis September 21, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site September 19, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference September 07, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board September 01, 2023 From Nexcella, Inc. Via GlobeNewswire U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma August 23, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board August 18, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) August 16, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting July 25, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site July 10, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial June 26, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors June 22, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors June 20, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors June 16, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors June 12, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site May 26, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) May 04, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris April 26, 2023 From Nexcella, Inc. Via GlobeNewswire Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting April 04, 2023 From Nexcella, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.